Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.1.02187
European Journal of Endocrinology, Vol 155, Issue 1, 131-136
Copyright © 2006 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macut, D.
Right arrow Articles by Milic, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macut, D.
Right arrow Articles by Milic, N.

CLINICAL STUDY

Oxidised low-density lipoprotein concentration – early marker of an altered lipid metabolism in young women with PCOS

Djuro Macut, Svetozar Damjanovic, Dimitrios Panidis1, Nikolaos Spanos1, Biljana Glisic2, Milan Petakov, David Rousso1, Anargyros Kourtis1, Jelica Bjekic3 and Natasa Milic4

Institute of Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Dr Subotica 13, 11000 Belgrade, Serbia, 1 Division of Endocrinology and Human Reproduction, 2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece, 2 Institute of Medical Biochemistry, Clinical Center of Serbia, Visègradska 26, 11000 Belgrade, Serbia, 3 Department of Endocrinology, CHC Bezanijska kosa, Autoput bb, 11000 Belgrade, Serbia and 4 Institute of Medical Statistics, School of Medicine, Dr subotica 15, 11000 Belgrade, Serbia

(Correspondence should be addressed to D Macut; Email: macut{at}EUnet.yu)

Objective: Women with polycystic ovary syndrome (PCOS) are assumed to be at increased risk for cardiovascular diseases. This study examined the variations in oxidised low-density lipoprotein (OxLDL) concentration in relation to insulin levels in young women with PCOS.

Design: Cross-sectional clinical study in tertiary cares research hospitals. A total of 179 women with PCOS (79 overweight) and 56 age- and body mass index-matched controls were examined.

Methods: Blood samples were collected in follicular phase of the cycle for the basal glucose, total-, high-density lipoprotein-cholesterol (HDL-C) and LDL-cholesterol, OxLDL, triglycerides, apolipoprotein–A1 (Apo-A1) and B (Apo-B), lipoprotein (a), insulin, testosterone and sex hormone-binding globulin (SHBG). Homeostatic model index (HOMA) and free androgen index (FAI) were determined.

Results: Overweight and normal weight women with PCOS had higher concentrations of OxLDL than their control counterparts (P=0.007 and 0.003 respectively). Both the basal insulin (P=0.003) and HOMA values (P<0.001) were significantly higher in overweight than normal weight patients. Testosterone and FAI were higher in patients than in the respective controls (P<0.001). The only independent predictor of increased OxLDL concentration in normal weight patients was Apo-B-to-Apo-A1 ratio (P<0.001, odds ratio (OR) 6.1; 95% confidence interval (CI) 2.3–16.4), while in obese PCOS, it was total cholesterol-to-high-density lipoprotein cholesterol ratio (P<0.001, OR 2.8; 95% CI 1.6–4.9).

Conclusion: Young normal weight and overweight PCOS women have similarly increased OxLDL levels. Our results may indicate the presence of primary alteration in lipid metabolism in patients with PCOS. To answer the question whether the alteration in LDL particle size can by itself pose a higher cardiovascular risk, a careful follow-up of these women is needed.




This article has been cited by other articles:


Home page
J. Med. EthicsHome page
S Giordano
Lives in a chiaroscuro. Should we suspend the puberty of children with gender identity disorder?
J. Med. Ethics, August 1, 2008; 34(8): 580 - 584.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
O. Valkenburg, R. P. M. Steegers-Theunissen, H. P. M. Smedts, G. M. Dallinga-Thie, B. C. J. M. Fauser, E. H. Westerveld, and J. S. E. Laven
A More Atherogenic Serum Lipoprotein Profile Is Present in Women with Polycystic Ovary Syndrome: A Case-Control Study
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 470 - 476.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
D. Glintborg, K. Hojlund, M. Andersen, J. E. Henriksen, H. Beck-Nielsen, and A. Handberg
Soluble CD36 and Risk Markers of Insulin Resistance and Atherosclerosis Are Elevated in Polycystic Ovary Syndrome and Significantly Reduced During Pioglitazone Treatment
Diabetes Care, February 1, 2008; 31(2): 328 - 334.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 European Society of Endocrinology.